Biogen banks on government coverage to restart stalled Alzheimer's drug sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Biogen (BIIB) PT Lowered to $390 at Oppenheimer
October 20, 2021 6:05 PM EDTOppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $450.00) while maintaining an Outperform rating.
The analyst commented, "Bolstered by a 3Q top- and bottom-line beat, BIIB outlined a number of steps to support the Aduhelm launch but deferred... More
Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k
October 20, 2021 9:00 AM EDTBiogen (NASDAQ: BIIB) stock is up about 1.5% in pre-open Wednesday after the company reported better-than-expected Q3 EPS.
BIIB reported Q3 EPS of $4.77 to beat the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
As far as full-year guidance is concerned, Biogen projects FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61.... More
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM EDTEarlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More
